<DOC>
	<DOCNO>NCT02969980</DOCNO>
	<brief_summary>This study conduct evaluate feasibility efficacy post-transplantation cyclophosphamide myeloablative reduced-intensity condition regimen allogeneic hematopoietic cell transplantation ( HCT ) patient myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide MDS</brief_title>
	<detailed_description>- Conditioning regimen low risk diseases A ) Cyclophosphamide 50 mg/kg/day i.v . daily 2 day ( day -6 -5 ) B ) Fludarabine 30 mg/m2/day i.v . daily 5 day ( day -6 -2 ) - Conditioning regimen high risk diseases A ) Busulfan 3.2 mg/kg/day i.v . daily For 4 day ( day -6 -3 ) patient age &lt; 55 year For 2 day ( day -6 -5 ) patient age ≥ 55 year B ) Fludarabine 30 mg/m2/day i.v . daily day -6 -2 ( 5 day ) - Harvest infusion donor hematopoietic cell Harvested peripheral blood mononuclear cell donor via leukapheresis infused recipient day 0 . Additional infusion day 1 make base judgement attend physician . - GVHD prophylaxis A ) Cyclophosphamide 25 mg/kg/day i.v . daily day 3 4 ( 2 day ) B ) Cyclosporine : 1.5 mg/kg i.v . every 12 hour begin day -1 change oral dose oral intake possible . The dosage taper begin day 30 60 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>MDS define WHO classification , chronic myelomonocytic leukemia ( CMML ) , acute myeloid leukemia ( AML ) evolve MDS A ) Lowerrisk disease : IPSS ≤ 1.0 bone marrow blast &lt; 5 % disease course HCT B ) Higherrisk disease : IPSS &gt; 1.0 bone marrow blast ≥ 5 % time point HCT AML progress MDS CMML Patients receive first HCT Patients appropriate hematopoietic cell donor A ) HLAmatched sibling donor B ) Unrelated donor C ) HLAmismatched familial donor 15 year old old Adequate performance status ( Karnofsky score 70 ) Adequate hepatic renal function ( AST , ALT , bilirubin &lt; 3.0 x upper normal limit , creatinine &lt; 2.0 mg/dL ) . Adequate cardiac function ( left ventricular ejection fraction 40 % heart scan echocardiogram ) Signed date informed consent must obtain recipient donor . Presence significant active infection Presence uncontrolled bleed Any coexist major illness organ failure Patients psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible Nursing woman , pregnant woman , woman childbearing potential want adequate contraception Patients diagnosis prior malignancy unless diseasefree least 5 year follow therapy curative intent ( except curatively treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>AML progress MDS</keyword>
	<keyword>CMML</keyword>
</DOC>